Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, now that the biopharma Woodstock is winding down and our series of daily back-to-back meetings will soon come to end. This calls for a celebratory cup of stimulation, which yields a bit of an adventure in the City by the Bay, since the choices are endless. Such problems, yes? Meanwhile, here are some items of interest. Hope you have a smashing day and do stay in touch …

Endo Pharmaceuticals (ENDO) received a grand jury subpoena from the feds seeking documents relating to drugs containing oxymorphone. The subpoena seeks records produced in past or pending lawsuits and others relating to safety and efficacy; overdoses; diversion; theft; overprescribing; abuse; misuse; dependency; withdrawal; addiction, and adverse events. The feds also want distribution and third-party agreements; sales and marketing, training, financial, compensation and corporate information; and documents relating to interactions with government agencies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!